{"protocolSection": {"identificationModule": {"nctId": "NCT00582114", "orgStudyIdInfo": {"id": "0306-13"}, "secondaryIdInfos": [{"id": "R01DK062030", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01DK062030"}, {"id": "NIH-NIDDK-5RO1-062030"}], "organization": {"fullName": "Indiana University", "class": "OTHER"}, "briefTitle": "Hypertension in Hemodialysis Patients (Aim 3)", "officialTitle": "Hypertension in Hemodialysis Patients"}, "statusModule": {"statusVerifiedDate": "2015-12", "overallStatus": "TERMINATED", "whyStopped": "Stopped by data safety monitoring board", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-08"}, "primaryCompletionDateStruct": {"date": "2013-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2013-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-20", "studyFirstSubmitQcDate": "2007-12-20", "studyFirstPostDateStruct": {"date": "2007-12-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-05", "resultsFirstSubmitQcDate": "2015-12-14", "resultsFirstPostDateStruct": {"date": "2016-01-18", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-12-14", "lastUpdatePostDateStruct": {"date": "2016-01-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Indiana University", "class": "OTHER"}, "collaborators": [{"name": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "We will directly test the hypothesis that an initial strategy of lisinopril-based therapy will be more effective than atenolol-based therapy in causing regression of left ventricular hypertrophy (LVH) over one year in patients with hemodialysis hypertension despite similar degree of BP reduction.", "detailedDescription": "This is a parallel group, active control, single-center, open-label, randomized controlled trial comparing the safety and efficacy of initial therapy with an angiotensin converting enzyme (ACE) inhibitor (lisinopril) vs. beta-blocker therapy (atenolol) each administered three times weekly after dialysis."}, "conditionsModule": {"conditions": ["Hemodialysis", "Hypertension", "Left Ventricular Hypertrophy"], "keywords": ["Hemodialysis", "Hypertension", "Left ventricular hypertrophy"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 200, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "ACTIVE_COMPARATOR", "description": "Atenolol", "interventionNames": ["Drug: Atenolol"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "Lisinopril", "interventionNames": ["Drug: Lisinopril"]}], "interventions": [{"type": "DRUG", "name": "Lisinopril", "description": "Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg.", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "Atenolol", "description": "Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg.", "armGroupLabels": ["1"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Primary End Point is the Regression of Left Ventricular Hypertrophy (LVH) by Echocardiographic Criteria From Baseline to 1 Year.", "description": "The primary outcome of the study was the average reduction in left ventricular mass indexed for body surface area from baseline to 1 year. A mixed model was used with left ventricular mass index (LVMI) as the outcome variable. Fixed effects were indicator variables for time, treatment and their interaction. Random effect was subject and statistical inference was made using the maximum likelihood estimator. No imputation was made for missing data.", "timeFrame": "Baseline, 6 months, 12 months"}], "otherOutcomes": [{"measure": "Serious Adverse Events and Cardiovascular Events That Led to Trial Termination", "description": "Cardiovascular events were counted by subject and included the following: myocardial infarction (MI), stroke, hospitalization for congestive heart failure (CHF), hospitalized angina, arrhythmias, cardiac arrest, coronary revascularization and heart valve replacement. Adverse events reported are those during the course of 12 months of participation in the trial. All serious adverse events were adjudicated by R.A. and A.D.S. who were masked to the drug assignment at the time of adjudication. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. The cardiovascular event rate was calculated by treatment group assignment. Incidence rate ratio (IRR) by treatment was then determined along with the 95% confidence intervals (95% CIs). As a post hoc analysis, we also determined the narrower definition of cardiovascular events per group that included MI, stroke, CHF, or cardiovascular death.", "timeFrame": "1 yr"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients on chronic hemodialysis for \\> 3 mos.\n2. Compliance with hemodialysis treatments as defined by less than one missed dialysis per month\n3. Hypertension as diagnosed by ambulatory blood pressure monitoring (ABPM) \\>135/75 mm Hg after participation in the ultrafiltration (UF) Trial, or those on no antihypertensive medications but unwilling to do UF Trial.\n4. Presence of LVH on echocardiogram defined as left ventricular mass index (LVMi) \\>104 g/m2 in women and \\>116 g/m2 in men.\n5. Willingness to give informed consent.\n\nExclusion criteria:\n\n1. Vascular event (stroke, myocardial infarction or limb ischemia requiring bypass) within previous six months\n2. Noncompliance with hemodialysis treatments\n3. Known drug abuse\n4. Chronic obstructive pulmonary disorder (COPD) requiring home oxygen\n5. Congestive Heart Failure Class III or IV.\n6. Body mass index \\> 40 kg/m2.\n7. Known contraindication to atenolol (severe heart failure, bradycardia, bronchial asthma, intolerance or allergy) or lisinopril (cough, pregnancy, intolerance or allergy)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Rajiv Agarwal, MD", "affiliation": "Indiana University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Indiana University", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}]}, "referencesModule": {"references": [{"pmid": "24398888", "type": "DERIVED", "citation": "Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014 Mar;29(3):672-81. doi: 10.1093/ndt/gft515. Epub 2014 Jan 6."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Atenolol", "description": "Atenolol: Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg."}, {"id": "FG001", "title": "Lisinopril", "description": "Lisinopril: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "100"}, {"groupId": "FG001", "numSubjects": "100"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "58"}, {"groupId": "FG001", "numSubjects": "46"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "54"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Kidney Transplant", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Stopped by data safety monitoring board", "reasons": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "20"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Atenolol", "description": "Atenolol: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg."}, {"id": "BG001", "title": "Lisinopril", "description": "Lisinopril: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "100"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "200"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "52.5", "spread": "11.7"}, {"groupId": "BG001", "value": "53.1", "spread": "13.5"}, {"groupId": "BG002", "value": "52.7", "spread": "12.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "69"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "58"}, {"groupId": "BG002", "value": "131"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "99"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "199"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Blacks", "categories": [{"measurements": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "172"}]}]}, {"title": "Non-blacks", "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "28"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "100"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "200"}]}]}]}, {"title": "Etiology of chronic kidney disease", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Diabetes mellitus", "categories": [{"measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "56"}]}]}, {"title": "Hypertension", "categories": [{"measurements": [{"groupId": "BG000", "value": "54"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "100"}]}]}, {"title": "Glomerulonephritis", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "9"}]}]}, {"title": "Polycystic kidney disease", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Other etiologies", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "34"}]}]}]}, {"title": "Dialysis vintage", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.2", "spread": "4.4"}, {"groupId": "BG001", "value": "3.9", "spread": "4.2"}, {"groupId": "BG002", "value": "4.1", "spread": "4.3"}]}]}]}, {"title": "Anuric", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68"}, {"groupId": "BG001", "value": "66"}, {"groupId": "BG002", "value": "134"}]}]}]}, {"title": "Education", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12", "spread": "2"}, {"groupId": "BG001", "value": "12", "spread": "2"}, {"groupId": "BG002", "value": "12", "spread": "2"}]}]}]}, {"title": "Comorbid conditions", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Diabetes mellitus", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "86"}]}]}, {"title": "Hospitalized heart failure", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "62"}]}]}, {"title": "Coronary artery disease", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "53"}]}]}, {"title": "Coronary revascularization", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "19"}]}]}, {"title": "Cerebrovascular disease", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "33"}]}]}, {"title": "Peripheral vascular disease", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "21"}]}]}]}, {"title": "Marital status", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Single", "categories": [{"measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "56"}, {"groupId": "BG002", "value": "109"}]}]}, {"title": "Married", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "42"}]}]}, {"title": "Divorced/separated", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "33"}]}]}, {"title": "Widowed", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "16"}]}]}]}, {"title": "Employed", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Working", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "18"}]}]}, {"title": "Not working", "categories": [{"measurements": [{"groupId": "BG000", "value": "67"}, {"groupId": "BG001", "value": "70"}, {"groupId": "BG002", "value": "137"}]}]}, {"title": "Retired", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "45"}]}]}]}, {"title": "Income", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< $25,000", "categories": [{"measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "80"}, {"groupId": "BG002", "value": "164"}]}]}, {"title": ">= $25,000", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "17"}]}]}, {"title": "Refused", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "19"}]}]}]}, {"title": "Smoking", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Current smoker", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "86"}]}]}, {"title": "Non-smoker", "categories": [{"measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "114"}]}]}]}, {"title": "Alcohol", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Drinks alcohol", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "46"}]}]}, {"title": "Does not drink alcohol", "categories": [{"measurements": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "81"}, {"groupId": "BG002", "value": "154"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "inches", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68.3", "spread": "4.1"}, {"groupId": "BG001", "value": "67.6", "spread": "3.7"}, {"groupId": "BG002", "value": "67.9", "spread": "3.9"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "85.1", "spread": "21.7"}, {"groupId": "BG001", "value": "80.9", "spread": "24.3"}, {"groupId": "BG002", "value": "83", "spread": "23.1"}]}]}]}, {"title": "Body mass index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.4", "spread": "7"}, {"groupId": "BG001", "value": "27.5", "spread": "8.3"}, {"groupId": "BG002", "value": "27.9", "spread": "7.7"}]}]}]}, {"title": "Access type", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Fistula", "categories": [{"measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "118"}]}]}, {"title": "Graft", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "30"}]}]}, {"title": "Catheter", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "52"}]}]}]}, {"title": "Blood flow rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "394.3", "spread": "30.9"}, {"groupId": "BG001", "value": "392.4", "spread": "36.4"}, {"groupId": "BG002", "value": "393.4", "spread": "33.7"}]}]}]}, {"title": "Dialysate flow rate", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "779.6", "spread": "61.9"}, {"groupId": "BG001", "value": "761.3", "spread": "82"}, {"groupId": "BG002", "value": "770.4", "spread": "73"}]}]}]}, {"title": "Dialysis duration", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "minutes", "classes": [{"title": "Prescribed dialysis duration", "categories": [{"measurements": [{"groupId": "BG000", "value": "239.4", "spread": "19"}, {"groupId": "BG001", "value": "239.4", "spread": "25.9"}, {"groupId": "BG002", "value": "239.4", "spread": "22.7"}]}]}, {"title": "Delivered dialysis duration", "categories": [{"measurements": [{"groupId": "BG000", "value": "224.1", "spread": "34.7"}, {"groupId": "BG001", "value": "219.8", "spread": "33.7"}, {"groupId": "BG002", "value": "222", "spread": "34.2"}]}]}]}, {"title": "Urea reduction ratio", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "%", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "74", "spread": "8"}, {"groupId": "BG001", "value": "76", "spread": "8"}, {"groupId": "BG002", "value": "75", "spread": "8"}]}]}]}, {"title": "Albumin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.6", "spread": "0.5"}, {"groupId": "BG001", "value": "3.6", "spread": "0.5"}, {"groupId": "BG002", "value": "3.6", "spread": "0.5"}]}]}]}, {"title": "Hemoglobin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "g/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.3", "spread": "1.2"}, {"groupId": "BG001", "value": "11.3", "spread": "1.4"}, {"groupId": "BG002", "value": "11.3", "spread": "1.3"}]}]}]}, {"title": "Creatinine", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "10.3", "spread": "3.5"}, {"groupId": "BG001", "value": "10", "spread": "3.6"}, {"groupId": "BG002", "value": "10.1", "spread": "3.6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Primary End Point is the Regression of Left Ventricular Hypertrophy (LVH) by Echocardiographic Criteria From Baseline to 1 Year.", "description": "The primary outcome of the study was the average reduction in left ventricular mass indexed for body surface area from baseline to 1 year. A mixed model was used with left ventricular mass index (LVMI) as the outcome variable. Fixed effects were indicator variables for time, treatment and their interaction. Random effect was subject and statistical inference was made using the maximum likelihood estimator. No imputation was made for missing data.", "populationDescription": "The primary outcome of the study was the average reduction in left ventricular mass indexed for body surface area from baseline to 1 year. The analysis was performed by intention to treat, if the patient received at least one dose of the randomized drug regardless of the availability of a post-baseline echocardiogram.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/m^2", "timeFrame": "Baseline, 6 months, 12 months", "groups": [{"id": "OG000", "title": "Atenolol", "description": "Atenolol: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg."}, {"id": "OG001", "title": "Lisinopril", "description": "Lisinopril: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}], "classes": [{"title": "LVMI Change from baseline, 6 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "-8.4", "spread": "5.1"}, {"groupId": "OG001", "value": "-3.4", "spread": "5.5"}]}]}, {"title": "LVMI Change from baseline, 12 months", "categories": [{"measurements": [{"groupId": "OG000", "value": "-21.5", "spread": "5.7"}, {"groupId": "OG001", "value": "-15.1", "spread": "6.2"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Serious Adverse Events and Cardiovascular Events That Led to Trial Termination", "description": "Cardiovascular events were counted by subject and included the following: myocardial infarction (MI), stroke, hospitalization for congestive heart failure (CHF), hospitalized angina, arrhythmias, cardiac arrest, coronary revascularization and heart valve replacement. Adverse events reported are those during the course of 12 months of participation in the trial. All serious adverse events were adjudicated by R.A. and A.D.S. who were masked to the drug assignment at the time of adjudication. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. The cardiovascular event rate was calculated by treatment group assignment. Incidence rate ratio (IRR) by treatment was then determined along with the 95% confidence intervals (95% CIs). As a post hoc analysis, we also determined the narrower definition of cardiovascular events per group that included MI, stroke, CHF, or cardiovascular death.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events/100 patient-years", "timeFrame": "1 yr", "groups": [{"id": "OG000", "title": "Atenolol", "description": "Atenolol: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg."}, {"id": "OG001", "title": "Lisinopril", "description": "Lisinopril: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}], "classes": [{"title": "Incidence rate, cardiovasular events", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.6"}, {"groupId": "OG001", "value": "58"}]}]}, {"title": "Incidence rate, combined MI, stroke, CHF, CV death", "categories": [{"measurements": [{"groupId": "OG000", "value": "13.5"}, {"groupId": "OG001", "value": "31"}]}]}, {"title": "Incidence rate, congest heart failure", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.2"}, {"groupId": "OG001", "value": "20.2"}]}]}, {"title": "Incidence rate, all-cause hospitalizations", "categories": [{"measurements": [{"groupId": "OG000", "value": "89.9"}, {"groupId": "OG001", "value": "144.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Cardiovascular events were counted by subject and included the following: myocardial infarction, stroke, hospitalization for congestive heart failure, hospitalized angina, arrhythmias, cardiac arrest, coronary revascularization and heart valve replacement. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. Incidence rate ratio (IRR) by treatment was then determined along with the 95%confidence intervals (95% CIs).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "Mixed Models Analysis", "paramType": "Hazard Ratio (HR)", "paramValue": "2.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.36", "ciUpperLimit": "4.23"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "As a post hoc analysis, we determined the narrower definition of cardiovascular events per group that included myocardial infarction, stroke, congestive heart failure or cardiovascular death. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. Incidence rate ratio (IRR) by treatment was then determined along with the 95%confidence intervals (95% CIs).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.02", "statisticalMethod": "Mixed Models Analysis", "paramType": "Hazard Ratio (HR)", "paramValue": "2.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.07", "ciUpperLimit": "5.21"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Hospitalization for congestive heart failure between groups was analyzed. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. Incidence rate ratio (IRR) by treatment was then determined along with the 95%confidence intervals.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.02", "statisticalMethod": "Mixed Models Analysis", "paramType": "Hazard Ratio (HR)", "paramValue": "3.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.08", "ciUpperLimit": "10.99"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "All-cause hospitalizations between groups were analyzed. The duration of participation in the study per subject, which according to the trial design could be up to 12 months, was determined. Incidence rate ratio (IRR) by treatment was then determined along with the 95%confidence intervals.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Mixed Models Analysis", "paramType": "Hazard Ratio (HR)", "paramValue": "1.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.18", "ciUpperLimit": "2.19"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Atenolol", "description": "Atenolol: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg.", "seriousNumAffected": 58, "seriousNumAtRisk": 100, "otherNumAffected": 44, "otherNumAtRisk": 100}, {"id": "EG001", "title": "Lisinopril", "description": "Lisinopril: Patients will be randomized into two groups, one that is beta blocker based, the other ACE inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to \\<140/90 mm Hg.", "seriousNumAffected": 70, "seriousNumAtRisk": 100, "otherNumAffected": 29, "otherNumAtRisk": 100}], "seriousEvents": [{"term": "Infections", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 30, "numAffected": 24, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 29, "numAffected": 20, "numAtRisk": 100}]}, {"term": "Access-related", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 17, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 30, "numAffected": 19, "numAtRisk": 100}]}, {"term": "Central nervous system", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Cancer-related complications", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Angina", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Congestive heart failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 15, "numAffected": 10, "numAtRisk": 100}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Peripheral vascular disease", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 100}]}, {"term": "Revascularization", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 100}]}, {"term": "Stroke", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Valve replacement surgery", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Cardiovascular death", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Noncardiovascular death", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Fractures", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Parathyroidectomy", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Biliary-related", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Bowel-related", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 100}]}, {"term": "Falls", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Gastrointestinal bleed", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 7, "numAffected": 5, "numAtRisk": 100}]}, {"term": "Hypertensive crisis", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 11, "numAffected": 10, "numAtRisk": 100}]}, {"term": "Hyperglycemia", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}]}, {"term": "Hyperkalemia", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 10, "numAffected": 10, "numAtRisk": 100}]}, {"term": "Hypoglycemia", "organSystem": "Endocrine disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 100}]}, {"term": "Hypotension with hospitalization", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 100}]}, {"term": "Miscellaneous", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 12, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 24, "numAffected": 18, "numAtRisk": 100}]}], "otherEvents": [{"term": "Fatigue", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 20, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 12, "numAffected": 6, "numAtRisk": 100}]}, {"term": "Gastrointestinal disorders", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 100}]}, {"term": "Upper respiratory infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 4, "numAffected": 2, "numAtRisk": 100}]}, {"term": "bradycardia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Intradialytic hypotension", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 100}]}, {"term": "tachycardia", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Dialysis access-related events", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}]}, {"term": "Hypertension", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 100}]}, {"term": "Other", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 19, "numAtRisk": 100}, {"groupId": "EG001", "numEvents": 29, "numAffected": 17, "numAtRisk": 100}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Rajiv Agarwal", "organization": "Professor of Medicine", "email": "ragarwal@iu.edu", "phone": "317-988-2241"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000017379", "term": "Hypertrophy, Left Ventricular"}, {"id": "D000006984", "term": "Hypertrophy"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000020763", "term": "Pathological Conditions, Anatomical"}, {"id": "D000006332", "term": "Cardiomegaly"}, {"id": "D000006331", "term": "Heart Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M10035", "name": "Hypertrophy", "asFound": "Hypertrophy", "relevance": "HIGH"}, {"id": "M19658", "name": "Hypertrophy, Left Ventricular", "asFound": "Left Ventricular Hypertrophy", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M22519", "name": "Pathological Conditions, Anatomical", "relevance": "LOW"}, {"id": "M9420", "name": "Cardiomegaly", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001262", "term": "Atenolol"}, {"id": "D000017706", "term": "Lisinopril"}], "ancestors": [{"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002316", "term": "Cardiotonic Agents"}, {"id": "D000020011", "term": "Protective Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}], "browseLeaves": [{"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M19924", "name": "Lisinopril", "asFound": "Amplitude", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M4568", "name": "Atenolol", "asFound": "Allowing", "relevance": "HIGH"}, {"id": "M18301", "name": "Felodipine", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M5572", "name": "Cardiotonic Agents", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}